Abdirasulova Zhainagul Abdirasulovna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdirasulova Zhainagul Abdirasulovna has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Mohd Faizan Siddiqui
International Medical Faculty, Osh State University, Osh City, Kyrgyzstan
2 shared publications - Ahmed M. Hussein1 shared publication
- Aiganysh Zhoomartovna Rysbaeva
Osh State University, International Medical Faculty
1 shared publication - Alhamza Abdulsatar Shaker
Al-Mansour University College
1 shared publication - Azhimamatova Rakhima Momunovna
International Medical Faculty, Osh State University, Osh, Kyrgyzstan
1 shared publication - Basim Hanoon Jabbar1 shared publication
Latest Publications
- Open Access
- 2 March 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 189-203
The Usage and Limitations of Gene Therapy Versus Stem Cell Therapy for Myotonic Dystrophy Type 1 (DM1): Special Focus on Immune Response
Muscular dystrophies include myotonic dystrophy (MD). Although there is no cure for this disorder, many treatments can manage symptoms and reduce disease development. Standard pharmacological treatments and rehabilitation methods have largely failed, prompting researchers to investigate stem cell and gene therapy options. This review will discuss gene therapy and stem cell therapy as adjuvant therapies for MD, including their benefits, drawbacks, and timeline for implementation. We searched PubMed, Scopus, Web of Science (WOS), Cochrane Library, and Embase from 1980 to 2024 for preclinical and clinical gene therapy papers for MD using keywords such as "myotonic dystrophy" and "gene therapy." A search for "myotonic dystrophy" and "Stem Cell" yielded studies on stem cell treatment for MD. The initial search found 50 gene therapy and 38 stem cell research articles. Following our exclusion and filtering criteria, we deleted 31 articles on gene therapy and 23 articles on stem cells. We found 19 gene therapy publications and 15 stem cell-based publications. Antisense oligonucleotides (ASO), CRISPR technology, and AAV vectors have become the most popular methods. Induced pluripotent stem cells (iPSCs) and muscle-derived progenitor cells (MuSCs) were important cellular sources for investigation or application. Most research focuses on myotonic dystrophy type I (DM1). It is widely established that AAV vector-induced immune responses can affect the safety and efficacy of genetic therapy. Specific stem cells may also modulate MD patients' immunological responses, improving prognosis. Using cytokines and monoclonal antibodies as adjuvants to treat this complex illness is becoming more common.
- 2 March 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 189-203
Open AccessThe Usage and Limitations of Gene Therapy Versus Stem Cell Therapy for Myotonic Dystrophy Type 1 (DM1): Special Focus on Immune Response
Muscular dystrophies include myotonic dystrophy (MD). Although there is no cure for this disorder, many treatments can manage symptoms and reduce disease development. Standard pharmacological treatments and rehabilitation methods have largely failed, prompting researchers to investigate stem cell and gene therapy options. This review will discuss gene therapy and stem cell therapy as adjuvant therapies for MD, including their benefits, drawbacks, and timeline for implementation. We searched PubMed, Scopus, Web of Science (WOS), Cochrane Library, and Embase from 1980 to 2024 for preclinical and clinical gene therapy papers for MD using keywords such as "myotonic dystrophy" and "gene therapy." A search for "myotonic dystrophy" and "Stem Cell" yielded studies on stem cell treatment for MD. The initial search found 50 gene therapy and 38 stem cell research articles. Following our exclusion and filtering criteria, we deleted 31 articles on gene therapy and 23 articles on stem cells. We found 19 gene therapy publications and 15 stem cell-based publications. Antisense oligonucleotides (ASO), CRISPR technology, and AAV vectors have become the most popular methods. Induced pluripotent stem cells (iPSCs) and muscle-derived progenitor cells (MuSCs) were important cellular sources for investigation or application. Most research focuses on myotonic dystrophy type I (DM1). It is widely established that AAV vector-induced immune responses can affect the safety and efficacy of genetic therapy. Specific stem cells may also modulate MD patients' immunological responses, improving prognosis. Using cytokines and monoclonal antibodies as adjuvants to treat this complex illness is becoming more common.
- Open Access
- 1 January 2026
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 11 (1)
Integration of Deep Learning and Mendelian Randomization Identifies Causal Biomarkers for CHD
- 1 January 2026
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 11 (1)
Open AccessIntegration of Deep Learning and Mendelian Randomization Identifies Causal Biomarkers for CHD
- Open Access
- 11 December 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 284-301
Exploring the Role of Immunotherapy in Cancer Treatment: A Systematic Review
In recent decades, immunotherapy has revolutionized the landscape of cancer treatment, offering novel therapeutic approaches that harness the body's immune system to combat malignancies effectively. This systematic review explores the pivotal role of immunotherapy in oncology, highlighting its diverse modalities, mechanisms of action, clinical applications, and ongoing challenges. Beginning with an overview of the historical evolution of cancer therapy, emphasis is placed on the emergence of immunotherapy as a cornerstone alongside traditional modalities such as chemotherapy and surgery. The review comprehensively examines various types of immunotherapy, including checkpoint inhibitors, chimeric antigen receptor T cells (CAR T cells) therapy, cytokine therapy, oncolytic viruses, and exosome-based therapies. Mechanisms behind these treatments are clarified, showing how they boost anti-tumor immune system reactions and thus enhance patient outcomes. Recent advancements for each modality are discussed, drawing on seminal studies and clinical trials cited in the literature. Furthermore, the review addresses clinical successes and challenges associated with immunotherapy, including resistance mechanisms and adverse effects, as highlighted in recent research. Technological innovations in drug delivery systems and biotechnology are explored as critical enablers of immunotherapy's efficacy and safety profiles. Finally, the review outlines future directions in the field, proposing strategies to overcome current limitations and optimize treatment efficacy. The synthesis of findings underscores the transformative impact of immunotherapy on cancer care and highlights opportunities for further research and clinical integration.
- 11 December 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 284-301
Open AccessExploring the Role of Immunotherapy in Cancer Treatment: A Systematic Review
In recent decades, immunotherapy has revolutionized the landscape of cancer treatment, offering novel therapeutic approaches that harness the body's immune system to combat malignancies effectively. This systematic review explores the pivotal role of immunotherapy in oncology, highlighting its diverse modalities, mechanisms of action, clinical applications, and ongoing challenges. Beginning with an overview of the historical evolution of cancer therapy, emphasis is placed on the emergence of immunotherapy as a cornerstone alongside traditional modalities such as chemotherapy and surgery. The review comprehensively examines various types of immunotherapy, including checkpoint inhibitors, chimeric antigen receptor T cells (CAR T cells) therapy, cytokine therapy, oncolytic viruses, and exosome-based therapies. Mechanisms behind these treatments are clarified, showing how they boost anti-tumor immune system reactions and thus enhance patient outcomes. Recent advancements for each modality are discussed, drawing on seminal studies and clinical trials cited in the literature. Furthermore, the review addresses clinical successes and challenges associated with immunotherapy, including resistance mechanisms and adverse effects, as highlighted in recent research. Technological innovations in drug delivery systems and biotechnology are explored as critical enablers of immunotherapy's efficacy and safety profiles. Finally, the review outlines future directions in the field, proposing strategies to overcome current limitations and optimize treatment efficacy. The synthesis of findings underscores the transformative impact of immunotherapy on cancer care and highlights opportunities for further research and clinical integration.
- Open Access
- 29 October 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 58-72
Efficacy of a Novel Nanoparticle RSV Vaccine in Preventing Infection in Older Adults: Phase III Clinical Trial
In this susceptible population, respiratory syncytial virus (RSV) can cause severe lower respiratory tract illness (LRTI), which can result in substantial morbidity and mortality. Adults who have RSV infection face a substantial burden. In this study, a Phase III, randomized, double-blind, placebo-controlled trial evaluated the effectiveness of a liposome-encapsulated perfusion F protein nanoparticle-based RSV vaccine (Nano-RSV) in preventing RSV infection. Adults who were enrolled and 60 years of age or older were given either Nano-RSV or a placebo. The incidence of laboratory-confirmed RSV LRTI exhibiting three or more symptoms (cough, fever, and shortness of breath) was the main outcome. Severity of symptoms and hospitalization rates for RSV LRTI were secondary endpoints. When compared to a placebo, the Nano-RSV vaccine dramatically lowered the risk of RSV LRTI (vaccine efficacy: 82.6%, 95% CI: 74.1–90.2%). RSV LRTI-related hospitalization rates were likewise markedly lower in the immunization group. The safety profile of the Nano-RSV vaccine was comparable to that of a placebo, and it was well-tolerated. These results imply that Nano-RSV may prove to be a secure and reliable prophylactic against RSV infection and its sequelae in the elderly.
- 29 October 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 58-72
Open AccessEfficacy of a Novel Nanoparticle RSV Vaccine in Preventing Infection in Older Adults: Phase III Clinical Trial
In this susceptible population, respiratory syncytial virus (RSV) can cause severe lower respiratory tract illness (LRTI), which can result in substantial morbidity and mortality. Adults who have RSV infection face a substantial burden. In this study, a Phase III, randomized, double-blind, placebo-controlled trial evaluated the effectiveness of a liposome-encapsulated perfusion F protein nanoparticle-based RSV vaccine (Nano-RSV) in preventing RSV infection. Adults who were enrolled and 60 years of age or older were given either Nano-RSV or a placebo. The incidence of laboratory-confirmed RSV LRTI exhibiting three or more symptoms (cough, fever, and shortness of breath) was the main outcome. Severity of symptoms and hospitalization rates for RSV LRTI were secondary endpoints. When compared to a placebo, the Nano-RSV vaccine dramatically lowered the risk of RSV LRTI (vaccine efficacy: 82.6%, 95% CI: 74.1–90.2%). RSV LRTI-related hospitalization rates were likewise markedly lower in the immunization group. The safety profile of the Nano-RSV vaccine was comparable to that of a placebo, and it was well-tolerated. These results imply that Nano-RSV may prove to be a secure and reliable prophylactic against RSV infection and its sequelae in the elderly.
- Open Access
- 20 March 2023
- Published by ROSOMED in Virtual Technologies in Medicine
- No. 1,p. 10-16
Multidisciplinary University Virtual Clinic Dimedus in Teaching Students of the International Medical Faculty of Osh State University
Mastering practical skills with the help of simulation technologies eliminates the risk to life, health of a patient and the stress of a trainee, allows you to conduct classes according to individual programs, without taking into account the operating mode of the clinic, makes it possible to repeatedly practice the skill and bring the manipulation to automatism. The article shows the effectiveness of the use of a multidisciplinary university virtual clinic Dimedus in practical classes in teaching clinical disciplines to foreign students of the International Medical Faculty of Osh State University.
- 20 March 2023
- Published by ROSOMED in Virtual Technologies in Medicine
- No. 1,p. 10-16
Open AccessMultidisciplinary University Virtual Clinic Dimedus in Teaching Students of the International Medical Faculty of Osh State University
Mastering practical skills with the help of simulation technologies eliminates the risk to life, health of a patient and the stress of a trainee, allows you to conduct classes according to individual programs, without taking into account the operating mode of the clinic, makes it possible to repeatedly practice the skill and bring the manipulation to automatism. The article shows the effectiveness of the use of a multidisciplinary university virtual clinic Dimedus in practical classes in teaching clinical disciplines to foreign students of the International Medical Faculty of Osh State University.